Currently Viewing:
American Society of Clinical Oncology Annual Meeting
Dr Peter Paul Yu Explains Current Challenges With Precision Medicine
July 18, 2018
Where Dr Victoria Villaflor Thinks the Future of Precision Medicine Is Headed
July 08, 2018
Dr Peter Paul Yu on Progress in the Move Toward Interoperability
July 06, 2018
Currently Reading
Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting
July 05, 2018
Dr Sara M. Tolaney: Standard of Care, Novel Approaches for Treatment of HER2-Positive Breast Cancer
June 28, 2018
Dr Victoria Villaflor Discusses How Novel Therapies Have Changed Cancer Treatment
June 26, 2018
Dr Peter Paul Yu: How Next-Generation Sequencing is Changing Cancer Care
June 21, 2018
Dr James Lin Chen on the Shift to Precision Medicine
June 18, 2018
Ellen Miller Sonet: The Importance of Cancer Care Providers Informing Patients of Treatment Costs
June 17, 2018
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16, 2018
Dr Leonard B. Saltz: The Role of Next-Generation Sequencing in Advancing Precision Medicine
June 14, 2018
Study Underscores Value of PROs in Improving Lung Cancer Survival
June 07, 2018
Discussing the Cost Burden of Cancer With Patients
June 06, 2018
Managing Cancer-Related Pain in the Era of the Opioid Crisis
June 06, 2018
Opdivo Plus Chemo Boosts Progression-Free Survival 26% Over Chemo Alone in Late-Stage NSCLC
June 04, 2018
Nearly Half of Patients With Metastatic CSCC Respond to Cemiplimab, on Fast Track at FDA
June 04, 2018
Cemiplimab, in GOG 3016, Looks to Break New Ground for Immunotherapy in Cervical Cancer
June 04, 2018
KEYNOTE-042 Confirms First-Line Pembrolizumab Superior to Chemotherapy in PD-L1–Low Advanced NSCLC
June 04, 2018
Phase 3 TAILORx Results Confirm Chemotherapy Unnecessary in 70% of Women With Early-Stage Breast Cancer
June 04, 2018

Dr Michael Thompson on Conducting Precision Medicine Trials in the Community Setting

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.


Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.

Transcript

What challenges are associated with conducting precision medicine trials in the community setting?

So, with precision medicine, you need to have tissue, and if you need new tissue, that is sometimes a barrier based on location or cost and toxicity of getting the new tissue. There is a barrier of getting the testing done, whether that’s on a research study or before the research program actually and the eligibility criteria, which may limit patient accrual. For many of these patients that have been through multiple lines of therapy and there aren’t a lot of great options, anything that slows things down can cause them to go from relatively healthy and able to go on a trial, to unhealthy and unable to go on the trial, or even dying. So, this has been seen, and we have to do things efficiently and fast in order to overcome these accrual barriers.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!